Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Digital Ischemia Associated with Profound Anemia: A Concerning Consequence of Treatment without Transfusions

Jessica A. Thomas, Kathleen Humkey, Ashley Dean, Jay Mehta, George Negrea

Blood (2022) 140 (Supplement 1): 11060–11061.

https://doi.org/10.1182/blood-2022-167842

Published: 2022

Journal Articles

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Matt Kalaycio, MD, O George Negrea, MD, Rebecca Elstrom, MD, Charles Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 192.

https://doi.org/10.1182/blood.V120.21.192.192

Published: 2012

Journal Articles

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Howard A. Liebman, MA, MD, Mansoor N Saleh, MD, James B. Bussel, MD, O George Negrea, MD, Heather Horne, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 622.

https://doi.org/10.1182/blood.V120.21.622.622

Published: 2012

Journal Articles

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Howard A Liebman, MD, Mansoor N Saleh, MD, James B Bussel, MD, Zale P Bernstein, MD, O George Negrea, MD, Anthony C Onyegbula, DO, Charles M Farber, MD, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2011) 118 (21): 3302.

https://doi.org/10.1182/blood.V118.21.3302.3302

Published: 2011

Journal Articles

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Mansoor N Saleh, MD, Howard Liebman, MD, Zale P. Bernstein, MD, O. George Negrea, MD, James B. Bussel, MD, Anthony C. Onyegbula, DO, Charles M Farber, MD, PhD, Rashid Abassi, MD, Thomas M. Cosgriff, MD, Kenneth Pennington, MD, Heather Horne, Nick Teoh, PhD, Asraf Gomaa, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2009) 114 (22): 1322.

https://doi.org/10.1182/blood.V114.22.1322.1322

Published: 2009

Journal Articles

Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.

O. George Negrea, MD, Steven L Allen, Kanti R. Rai, MD, Rebecca Elstrom, MD, Rashid Abassi, MD, Charles M Farber, MD, PhD, Nick Teoh, PhD, Heather Horne, William A Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2009) 114 (22): 3757.

https://doi.org/10.1182/blood.V114.22.3757.3757

Published: 2009

NARROW

Digital Ischemia Associated with Profound Anemia: A Concerning Consequence of Treatment without Transfusions

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Digital Ischemia Associated with Profound Anemia: A Concerning Consequence of Treatment without Transfusions

Monotherapy with Subcutaneous (SC) Injections of Low Doses of Humanized Anti-CD20 Veltuzumab Is Active in Chronic Lymphocytic Leukemia (CLL)

Phase I/II Study of Monotherapy with Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab for Treatment of Relapsed Immune Thrombocytopenia (ITP).

Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only